2018 ESC Guidelines for the management of cardiovascular ... · 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Task Force Expert Type of Relationship

Bauersachs Johann 1- Financial Declaration

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Astra Zeneca : ACS, heart Failure, Kidney diesease (2016)

- Boehringer-Ingelheim : Afib, Diabetes mellitus (2016)

- Abiomed : CAD, cardigenic shock (2016)

- Heartware : Heart Failure (2016)

- Berlin Chemie AG : Hypertension, CAD (2016)

- Daiichi Sankyo : ACS, Afib (2016-2017)

- Bayer : Afib, heart failure (2016-2017)

- Bristol Myers Squibb : Afib, heart failure (2016-2017)

- Merck Sharp & Dohme : CAD, Hypercholesterolemia (2016-2017)

- Medtronic : Heart Failure (2016-2017)

- Servier : Heart Failure (2016-2017)

- Thoratec/SJM : Heart Failure (2016-2017)

- Pfizer : Heart Failure, Afib (2016-2017)

- Biotronik : Heart Failure, CAD (2016-2017)

- Novartis : Hypertension, Heart Failure (2016-2017)

- Orion : Acute Heart Failure (2017)

- Boehringer-Ingelheim : Afib, Diabetes mellitus, Heart Failure (2017)

- CVRx : Heart Failure (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Bayer : Vascular remodeling (2016)

24/08/2018

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Task Force

Expert Type of Relationship with Industry

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

1/49

Bauersachs Johann - Medtronic : CAD (2016-2017)

- Abiomed : cardiogenic shock (2016-2017)

- Zoll Medical : Arrhythmia (2017)

- CVRx : Heart Failure (2017)

Blomstrom-Lundqvist Carina

1- Financial Declaration


- Biosense Webster : ablation (2016)

- Atricure : AF ablation (2016)

- Pfizer : anticoagulation (2016)

- Boston Scientific : devices (2016)

- Bayer : anticoagulation (2016-2017)

- Sanofi Aventis : anticoagulation (2016-2017)

- Merck Sharp & Dohme : anticoagulation (2016-2017)

- Medtronic : devices (2016-2017)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Bayer : anticoagulation (2016)

- Boston Scientific : Arrhythmia (2016)

- Medtronic : AF (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- Medtronic : AF (2016-2017)

- Cardiomems : drug (2016-2017)

24/08/2018




2/49

Cifkova Renata

Nothing to be declared (2017)



- Ferrer Internacional : cardiovascular (2016)

- Merck Sharp & Dohme : cardiovascular (2016)

- Amgen Czech republic : cardiovascular (2016)

De Bonis Michele 1- Financial Declaration


- Medtronic : valve prostheses (2016-2017)

Iung Bernard 1- Financial Declaration


- Edwards Lifesciences : Heart Valve Prostheses (2016-2017)

- Boehringer Ingelheim : Anticoagulants (2017)

- Novartis : Heart failure drugs (2017)

Johnson Mark

Nothing to be declared (2016-2017)

Kintscher Ulrich 1- Financial Declaration


- Daiichi Sankyo : Anticoagulation (2016)

- Sanofi Aventis : Dyslipidemia (2016)

24/08/2018




3/49

Kintscher Ulrich - Sciarc GmbH : Heart failure (2016)

- Berlin Chemie AG : Hypertension (2016-2017)

- Novartis : Heart Failure (2017)

- Bayer AG : Hypertension (2017)

- CTI Congress Management : Hypertension (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Bayer AG : Heart Failure (2017)

E - Research funding (personal).- Bayer AG : Heart Failure (2016)

2- Other Positions of Influence

2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- German Hypertension League (2017)

Kranke Peter 1- Financial Declaration


- Acacia Ltd : Antiemetics (2016-2017)

- Medtronic : Capnography (2016-2017)

- FreseniusKabi : Infusion / Anaesthetics (2016-2017)

- BBraun : Pain Management (2016-2017)

- Gruenenthal : Pain Management (2016-2017)

- The Medicines Company : Pain medicine (2016-2017)

- Ratiopharm : Vasopressors (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- Acacia Ltd. : Antiemetics Phase III Trials (2016-2017)

24/08/2018




4/49

Kranke Peter - Ministry of Health, Bavaria (Germany) : Telemedicine / Critical Care (2016-2017)

Lang Irene Marthe 1- Financial Declaration


- Menarini : coronary artery disease (2016)

- Actelion : pulmonary hypertension (2016)

- Bayer AG : pulmonary hypertension (2016)

- AOPOrphan : pulmonary hypertension (2016)

- Medtronic : vascular intervention (2016)

- Kaneka : interventional devices (2017)

- Medtronic : medical devices (2017)

- Actelion : Pulmonary Hypertension medications (2017)

- Ferrer Internacional : Pulmonary Hypertension medications (2017)

- MSD : Pulmonary Hypertension medications (2017)

- AOP Orphan Pharmaceuticals : Pulmonary Hypertension medications (2017)


- Servier : heart failure (2016)


- AOP Orphan Pharmaceuticals : Pulmonary Hypertension medications (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Actelion : pulmonary hypertension (2016)

- AOP Orphan Pharmaceuticals : pulmonary hypertension (2016)


24/08/2018




5/49

Lang Irene Marthe - AOP Orphan Pharmaceuticals : Pulmonary Hypertension medications (2017)

Morais Joao 1- Financial Declaration


- Daiichi Sankyo : Anticoagulants (2016)

- Bayer Healthcare : Anticoagulants (2016)

- Bristol Myers Squibb : Anticoagulants (2016)


- Astra Zeneca : Antiplatelets (2016)

- Merck Sharp & Dohme : Antiplatelets, lipids (2016)

- Boston Scientific : Left Atrial Apendage Closure (2016)

- Amgem : Lipids (2016)

- Merck Sharp & Dohme : ATOZET (2017)

- Boehringer-Ingelheim : Dabigatrano (2017)

- Novartis : Entresto (2017)

- Servier : Ivanradina (2017)

- Bial Portela : Lipids (2017)

- Menarini : Ranolazina (2017)

- Bayer Healthcare : Rivaroxaban (2017)

- Astra Zeneca : Ticagrelor (2017)

Pieper Els Petronella G


24/08/2018




6/49

Presbitero Patrizia


Price Susanna



2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring. - Employed full-time by the UK National Health Service as a clinical consultant in intensive care and cardiology at the Royal Brompton Hospital (2017)

Regitz-Zagrosek Vera 1- Financial Declaration

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Vinzenz von Paul Kliniken gGmbH : Hospital (2016)

- Novartis : cardiovascular medicine (2017)

- Berlin Chemie AG : cardiovascular medicine (2017)

- Pfizer Pharma GmbH : cardiovascular medicine (2017)

- Verband deutscher Unternehmerinnen : Gender medicine (2017)

- Zahnmedizinisches Fortbildungszentrum : Gender medicine (2017)

- Saarländischer Hausärzteverband : Gender medicine (2017)

- Cognomed : Heart failure therapy (2017)

Roos-Hesselink Jolien W


Rosano Giuseppe M C


7/824/08/2018




7/49

Seeland Ute


Swan Lorna 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry. - British Heart Foundation : Grant funding to the ACHD Unit (2016-2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - Member of the UK Clinical Reference Group (governmental organisation) for congenital heart disease. (2016)

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Council member of the BCCA (British Congenital Cardiac Association) (2016)

Tommaso Simoncini 1- Financial Declaration

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott : Pregnancy (2016)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - SunMedical : Surgical devices for Pelvi organ prolapse treatment (2017)

- Laborest : Urinary tract Infection (2017)

Warnes Carole A



C - Receipt of royalties for intellectual property. - Book : general cardiology/congenital heart disease (2017)

8/824/08/2018




8/49

Aboyans Victor 1- Financial Declaration


- Amgen : Hyperlipidemia (2017)

- Novartis : Hypertension (2017)

- Boehringer-Ingelheim : Oral anticoagulation (2017)

- Bayer Healthcare : Oral anticoagulation (2017)

- Pfizer/BMS alliance : Oral anticoagulation (2017)

Agewall Stefan 1- Financial Declaration


- Astra Zeneca : Antiplatelet treatment (2017)

Banu Cristiana


Barbato Emanuele 1- Financial Declaration


- Boston Scientific : Education courses on rotational atherectomy (2017)

- Abbott Vascular : Educational courses on FFR (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : Unrestricted grant for an investigator-driven study (2017)

Barysiene Jurate 1- Financial Declaration


- Servier : antihypertensive treatment (2017)

- Pfizer : Apixaban (2017)

24/08/2018

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers



9/49

Barysiene Jurate - Boehringer-Ingelheim : Dabigatran (2017)

- Bayer : Rivaroxaban (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Apama Medical Inc. : electrohysiology, AF treatment (2017)

- BackBeat Medical Inc. : electrophysiology, hypertension treatment (2017)

Benlamin Hisham


Bertelli Luca


Bouma Berto 1- Financial Declaration


- Abbott Vascular : mitraclip (2017)

Bueno Hector 1- Financial Declaration


- Pfizer : Apixaban (2017)

- Bristol Myers Squibb : Apixaban (2017)

- Bayer : Aspirin, rivaroxaban (2017)

- MEDSCAPE-the heart.og : Inespecific (2017)

- Sanofi Aventis : PCSK9 inhibitors (2017)

- Novartis : Serelaxin, ACZ885, AHF Academy, (2017)


- Ferrer Internacional : Trinomia (polypill) (2017)

24/08/2018




10/49

Bueno Hector B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.


E - Research funding (personal).- BMS : CV013-011 - STANDUP-AHF trial (2017)

- Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017)

- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2017)

- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- VP elect. Spanish Society of Cardiology FAHA (2017)

Calda Pavel


Caluk Jasmin


Caruana Maryanne


Coca Antonio 1- Financial Declaration


- Merck Serono : Bisoprolol-Amlodipine (2017)

- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2017)

- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2017)

24/08/2018




11/49

Collet Jean-Philippe 1- Financial Declaration


- Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017)

- Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017)

- Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017)

- Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017)

- Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017)

- Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017)

- Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

- Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

Coman Ioan Mircea 1- Financial Declaration


- Daiichi Sankyo : anticoagulants (2017)

- Johnson & Johnson : antithrombotic (2017)

- Bayer AG : antithrombotic (2017)

- Sanofi Aventis : dyslipidemia (2017)

- Fournier Laboratories : dyslipidemia (2017)

- Amgen Inc : dyslipidemia , (2017)

24/08/2018




12/49

Coman Ioan Mircea - Novartis : HF (2017)

- Vifor International : iron deficiency (2017)

- Actelion : PHT (2017)


- Daiichi Sankyo : anticoagulants (2017)

- Johnson & Johnson : antithrombotic (2017)

- Bayer AG : antithrombotic (2017)

- Sanofi Aventis : dyslipidemia (2017)

- Amgen Inc : dyslipidemia (2017)

- Fournier Laboratories : dyslipidemia (2017)

- Novartis : HF (2017)

- Vifor International : iron deficiency (2017)

- Actelion : PHT (2017)

De Backer Julie


Deaton Christi 1- Financial Declaration

E - Research funding (personal).- GlaxoSmithKline : COPD (patient media) (2017)

Delgado Victoria 1- Financial Declaration


- Abbott Vascular : Mitraclip (2017)

24/08/2018




13/49

Delgado Victoria D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : pacemakers (2017)

- Medtronic : pacemakers (2017)

- Biotronik : pacemakers (2017)

- Edwards Lifesciences : valves (2017)

Di Salvo Giovanni


Dubrava Juraj 1- Financial Declaration


- Boehringer-Ingelheim : idarucizumab, dabigatran (2017)

- Servier : ivabradine (2017)

- Bayer : rivaroxaban (2017)

- Novartis : sacubitril/valsartan (2017)

Erwin John


Estensen Mette-Elise


Fitzsimmons Samantha


Fitzsimons Donna


24/08/2018




14/49

Furenas Eva


Gaemperli Oliver 1- Financial Declaration


- GE Healthcare : Imaging (2017)

Garbi Madalina 1- Financial Declaration


- Edwards Lifesciences : Once only fee for participation to a group meeting regarding symptoms in aortic stenosis (2017)

Geraci Giovanna


Gevaert Sofie 1- Financial Declaration


- Astra Zeneca : acute coronary syndromes (2017)

- Novartis : heart failure (2017)

- Merck Sharp & Dohme : heart failure, prevention (2017)

Giannakoulas George 1- Financial Declaration


- Menarini : Chronic coronary artery disease (2017)

- Astra Zeneca : Coronary Artery Disease (2017)

- Novartis : Heart Failure (2017)

- Servier : Heart Failure-Chronic Coronary Artery Disease (2017)

24/08/2018




15/49

Giannakoulas George - Mylan : Hyperlidaemia (2017)

- Sanofi Aventis : Hyperlipidemia (2017)

- MSD : Hyperlipidemia-Pulmonary Hypertension (2017)

- Actelion : Pulmonary Hypertension (2017)

- GlaxoSmithKline : Pulmonary Hypertension (2017)

- Lilly : Pulmonary Hypertension (2017)

- Elpen Pharmaceuticals : Pulmonary Hypertension (2017)

- Bayer : Thromboembolic Disease (2017)

- Boehringer-Ingelheim : Thromboembolic Disease (2017)

- Pfizer : Thrombosis- Pulmonary Hypertension (2017)

Gotcheva Nina 1- Financial Declaration


- Boehringer-Ingelheim, Sanofi, Actavis-Teva : Dabigatran, Alirocumab (2017)

Gratii Cristina


Haddour Laila


Hammoudi Naima


Heracleous Hera


24/08/2018




16/49

Hindricks Gerhard 1- Financial Declaration


- Abbott : Pacemaker, Ablation (2017)

- Biosense Webster : Pacemaker, Ablation (2017)

- Biotronik : Pacemaker, catheter (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Abbott, Biotronik, Medtronic, Boston Scientific : Electropyhsiology, arrhythmias (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the

Helios Hospital Group. (2017)

Hoffman Piotr 1- Financial Declaration


- Servier : drugs (2017)

- Actelion : Drugs (2017)

- Sanofi Aventis : DRugs (2017)

- Berlin Chemie AG : DRugs (2017)

- Recordati International : drugs (2017)

- Abbott : MitraCip (2017)

Ibrahimi Pranvera


24/08/2018




17/49

Jondeau Guillaume 1- Financial Declaration



D - Research funding (departmental or institutional) from healthcare industry.- Novartis : heart failure (2017)

Juni Peter 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : Anti-platelet Therapy (2017)

- Biotronik : Drug-eluting stents (2017)

- Biosensors International Group : Drug-eluting stents (2017)

- The Medicines Company : Thrombin inhibitors (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly

and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)

Kaaja Risto Juhani 1- Financial Declaration


- Sanofi Aventis : LMWH (2017)

- Leo Pharma : LMWH (2017)

Kadry Zeina


24/08/2018




18/49

Katus Hugo 1- Financial Declaration


- Daiichi Sankyo : Lixiana_NOAK (2017)


- Bayer Vital : Xarelto-NOAK (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : Biobank (2017)

- Philips : MRT (2017)

Kiss Robert Gabor 1- Financial Declaration


- Sanofi Aventis steering committee member : coordination of a PCSK9 study (2017)

- TIMI group steering committee member : diabetes drug therapy (2017)

- Cleveland Clinic Research Foundation : fish oil (2017)


- Astra Zeneca : diabetes oral drugs (2017)

- Pfizer : NOAC (2017)

- Bayer AG : NOAC (2017)

- Boehringer-Ingelheim : NOAC, empaglifozin (2017)

- Amgen : PCSK9 inhibitor (2017)

- MSD : sitagliptin, ezetimibe, edoxaban (2017)

Kluin Jolanda


24/08/2018




19/49

Knuuti Juhani 1- Financial Declaration


- Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017)

- GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)

Kozelj Mirta


Lancellotti Patrizio 1- Financial Declaration


- Servier : Ischemic Heart Disease (2017)


- Bayer : NOAC (2017)

Leclercq Christophe 1- Financial Declaration


- Abbott : devices (2017)

- Boston Scientific : devices (2017)

- Medtronic : devices (2017)

- Biotronik : devices (2017)

- LIvanova : devices (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Biotronik : devices (2017)

24/08/2018




20/49

Lionis Christos 1- Financial Declaration


- Gilead : Advisory Board fees (topic relevant to vaccinations in adults) (2017)

C - Receipt of royalties for intellectual property.- Olvos SA : Cretan Iama (2017)

Lunegova Olga


Mascherbauer Julia 1- Financial Declaration


- Pfizer : cardiac amyloidosis (2017)

- AOP Orphan Pharmaceuticals : pulmonary hypertension (2017)

Maser Maarja


McDonagh Theresa 1- Financial Declaration


- Vifor International : Ferrinject (2017)

- Novartis : Honoraria (2017)

- Bayer AG : Honoraria (2017)

Meier Pascal 2- Other Positions of Influence

2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- British medical journal editor British society of cardiology board member (2017)

24/08/2018




21/49

Mintale Iveta 1- Financial Declaration


- Boehringer-Ingelheim : speaker fees (2017)

- Servier : speaker fees (2017)

- Berlin Chemie AG : speaker fees (2017)

- Merck Serono : speaker fees (2017)

Mitchenko Olena 1- Financial Declaration


- Sanofi Aventis : Dyslipidemia (2017)

Moiseeva Olga 1- Financial Declaration


- Pfizer : Pulmonary hypertension (2017)

- Actelion : Pulmonary hypertension (2017)

- Bayer AG : Pulmonary hypertension (2017)


- Pfizer : Pulmonary hypertension (2017)

- Actelion : Pulmonary hypertension (2017)

Moons Philip


24/08/2018




22/49

Mounier Vehier Claire 1- Financial Declaration


- Bayer Healthcare : consultancy (2017)

- Merck Sharp & Dohme : consultancy and speaker (2017)

- Novartis : speaker (2017)

- Resmed : speaker (2017)

- Novo-Nordisk : speaker (2017)

- Abbott : Speaker fees (2017)

- Astra Zeneca : speaker fees (2017)

- Boehringer-Ingelheim : speaker fees (2017)

Mourali Mohamed Sami


Nelson-Piercy Catherine 1- Financial Declaration


- UCB : RHEUMATOLOGY - cimzia certulizumab (2017)


- ALLIANCE PHARMA : ANTIEMETIC - diclectin (2017)

- Sanofi Aventis : LMWH - clexane - enoxaparin (2017)

Ozer Necla


24/08/2018




23/49

Pantazis Antonios 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Reata Pharmaceuticals : MOXIe study - RTA 408 in the Treatment of Friedreich’s Ataxia (2017)

Pasquet Agnes A 1- Financial Declaration


- Actelion : pulmonary hypertension, received a registration for a congress (2017)

- Servier : speaker fee for organisaton of a congress an a paper on bipressil ( published in2017) (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Catholic univerisity of Leuven , 1200 Brussels : cardiology cardiac valves disease (2017)

- Bayer : unspecifed research grant (2017)

- Daiichi Sankyo : unspecifed research grant (2017)

E - Research funding (personal).- Catholic univerisity of Leuven , 1200 Brussels : cardiology cardiac valves disease (2017)

Petris Antoniu Octavian 1- Financial Declaration


- Servier : Angina (2017)

- Pfizer : Apixaban Eliquis (2017)

- Boehringer-Ingelheim : Dabigatran PRADAXA (2017)

- Societatea Romana de Cardiologie : Electrocardiography for ICU nurses (2017)

- Novart Pharma Services Romania SRL : Entresto (2017)

- Servier : Heart failure (2017)

- Astra Zeneca : Hypertension (2017)

- Servier : Hypertension (2017)

24/08/2018




24/49

Petris Antoniu Octavian - S.C. Berlin-Chimie Menarini SRL : Hypertension (2017)

- GTS Solutions SRL : Polypill (2017)

- Astra Zeneca : Ticagrelor Brilique (2017)


- Novartis : International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure REPORT-HF (2017)

Piepoli Massimo Francesco


Piruzyan Armen 1- Financial Declaration


- Servier : Hypertension, SIHD (2017)

- Takeda Pharmaceuticals : Hypertension, Heart failure (2017)

- Bayer : Rivaroxaban - NOACs (2017)

Ponikowski Piotr 1- Financial Declaration


- Boehringer-Ingelheim : anticoagulant, diabetes (2017)

- Respicardia : devices (2017)


- Cardiorentis : heart failure (2017)

- Berlin Chemie AG : heart failure (2017)

- Bayer Healthcare : heart failure (2017)

- Vifor Pharma ltd : heart failure (2017)

24/08/2018




25/49

Ponikowski Piotr - CIBIEM : heart failure (2017)

- Servier : heart failure, coronary artery disease (2017)

- Amgen : heart failure, lipids (2017)

- Pfizer : lipids, heart failure (2017)


- Respicardia : anticoagulant (2017)

- BioControl : devices (2017)

- Cardionomic : devices (2017)

- Impuls Dynamics : devices (2017)


- Bayer Healthcare : heart failure (2017)

- CIBIEM : heart failure (2017)

- National Institute of Health : heart failure (2017)

- Servier : heart failure, coronary artery disease (2017)

- Amgen : heart failure, lipids (2017)

- European Union grant : heart failure, prevention (2017)

Porter Avital


Prieto Arevalo Raquel


24/08/2018




26/49

Prystrom Andrei


Richter Dimitrios 1- Financial Declaration


- Edwards Lifesciences : aortic stenosis (2017)

- Menarini : CAD- hypertension (2017)

- Novo-Nordisk : diabetes (2017)

- Novartis : hypertension (2017)

- Unipharma : hypertension-thrombosis (2017)

- Abbott : lipids (2017)

- Amgen : lipids (2017)

- Sanofi Aventis : Lipids (2017)

- Lilly : Lipids (2017)

- Unilever : lipids (2017)

- Merck Sharp & Dohme : lipids (2017)

- Vianex : lipids (2017)

- Galenica : Lipids (2017)

- Teva Pharmaceutical Industries : lipids, hypertension (2017)

- Bayer Healthcare : Thrombosis (2017)

24/08/2018




27/49

Rocca Bianca 1- Financial Declaration


- Bayer AG : Aspirin, Rivaroxaban (2017)

E - Research funding (personal).- Italian Medicines Agency (AIFA) : aspirin (2017)


2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.- NA (2017)

Roffi Marco 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : Stents (2017)

- Medtronic : Stents (2017)

- Biotronik : stents (2017)

- Terumo Inc : stents (2017)

- Abbott Vascular : stents (2017)

Rosenkranz Stephan 1- Financial Declaration


- BMS : Anticoagulation (2017)

- Vifor International : heart failure (2017)

- MSD : heart failure, pulmonary hypertension (2017)


- United Therapeutics : Pulmonary Hypertension (2017)

- Arena Pharmaceuticals : pulmonary hypertension (2017)

24/08/2018




28/49

Rosenkranz Stephan - Pfizer : Pulmonary Hypertension, Anticoagulants (2017)

- Novartis : Pulmonary Hypertension, Heart Failure (2017)

- Bayer : Pulmonary Hypertension, Heart Failure, Anticoagulants (2017)


- Abbott : Steering committee member (2017)

- Bayer : Steering Committee member (2017)

- Actelion : Steering Committee member (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Bayer : Pulmonary Hypertension (2017)


- United Therapeutics : Pulmonary Hypertension (2017)

- Novartis : Pulmonary Hypertension, Heart Failure (2017)

Rybak Karin 1- Financial Declaration


- Bayer Healthcare : Anticoagulants (NOAKs) (2017)

- Vifor International : Heart Failure (2017)

- Medtronic : ICD, CRT, pacemaker (2017)

- Astra Zeneca : Ticagrelor / Coronary heart disease (2017)

Samadov Fuad


24/08/2018




29/49

Sarkozy Andrea 1- Financial Declaration


- Biosense Webster : Electrophysiology (2017)

Schwerzmann Markus 1- Financial Declaration



- Merck Sharp & Dohme : Pulmonary Hypertension (2017)

- Orpha Suisse : Pulmonary Hypertension (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Swiss National Science Foundation : Adult Congenital Heart Disease (2017)


Shlyakhto Evgeny 1- Financial Declaration


- Krka Pharma : Arterial Hypertension (2017)

- Novartis : Arterial Hypertension, Heart Failure (2017)

- Merck Sharp & Dohme : Atherosclerosis (2017)

- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2017)

- Pfizer : General Cardiology (2017)

Silversides Candice


24/08/2018




30/49

Simpson Iain A 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Member and Past President of the British Cardiovascular Society Member of the Management Board of the American

College of Cardiology National Cardiovascular Data Registries (2017)

Skoric Bosko 1- Financial Declaration


- Novartis : Entresto (2017)

Sliwa-Hahnle Karen


Sousa Uva Miguel


Srbinovska-Kostovska Elizabeta


Tamargo Juan Luis 1- Financial Declaration


- Menarini : Angina, diabetes (2017)


- Servier : Committee Member (2017)

- Ferrer Internacional : Polypill (2017)

Thorne Sara 1- Financial Declaration

C - Receipt of royalties for intellectual property.- Oxford University Press : Book (2017)

24/08/2018




31/49

Thrainsdottir Inga Sigurros


Vakhtangadze Tamar


Van De Velde Marc 1- Financial Declaration


- Janssen-Cilag : Anesthestics (2017)

- Smiths Medical : Epidural and peripheral nerve blocks and pumps (2017)

- Heron : Experimental drug for analgesia (2017)

- Sintetica : Local Anesthestics (2017)

- Nordic Pharma : Local anesthestics and coagulation drugs (2017)

- MSD : Muscle relaxants and reversal agents (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Baxter : IV Fluids (2017)

- Air liquide : Xenon (2017)

Vejlstrup Niels 1- Financial Declaration


- Biosense Webster : intracardiac ultrasound (2017)


- St Jude Medical : intracardiac ultrasound (2017)

Vujisic-Tesic Bosiljka


24/08/2018




32/49

Williams Bryan 1- Financial Declaration


- Boehringer-Ingelheim : Hypertension (2017)

- Daiichi Sankyo : Hypertension (2017)

- Novartis : Hypertension (2017)

- Servier : Hypertension (2017)

- Vascular Dynamics Inc, USA : Hypertension - device based therapyy (2017)

- Pfizer : Hypertension and cardiovascular risk management (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- Trustee of BP UK - a patient's association (2017)

Windecker Stephan 1- Financial Declaration


- Bayer AG : General Cardiology (2017)

- Abbott : Invasive Cardiology (2017)

- Boston Scientific : Invasive Cardiology (2017)

- Edwards Lifesciences : invasive Cardiology (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Abbott : General Cardiology (2017)

- Boston Scientific : General Cardiology (2017)

- St. Jude Medical : General Cardiology (2017)

- Amgen Inc. : General Cardiology (2017)

24/08/2018




33/49

Windecker Stephan - Symetis SA : Invasive Cardiology (2017)

- Biotronik : Invasive Cardiology (2017)

- Terumo Inc : Invasive Cardiology (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational

and Entreprenieur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)

Zamorano Gomez Jose Luis



- Bayer : afib (2017)

- Pfizer : Afib (2017)

24/08/2018




34/49

Aboyans Victor 1- Financial Declaration


- Amgen : Hyperlipidemia (2016-2017)

- Novartis : Hypertension (2016-2017)

- Boehringer-Ingelheim : Oral anticoagulation (2016-2017)

- Bayer Healthcare : Oral anticoagulation (2016-2017)

- Pfizer/BMS alliance : Oral anticoagulation (2016-2017)

Agewall Stefan 1- Financial Declaration


- Astra Zeneca : Antiplatelet treatment (2016-2017)

Barbato Emanuele 1- Financial Declaration


- St Jude Medical : Educational courses on FFR (2016)

- Boston Scientific : Education courses on rotational atherectomy (2016-2017)

- Abbott Vascular : Educational courses on FFR (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : Unrestricted grant for an investigator-driven study (2016-2017)

Bueno Hector 1- Financial Declaration


- Abbott : BVS (2016)

- Servier : ivabradine (2016)

- Novartis : Serelaxin, ACZ885, AHF Academy (2016)

24/08/2018

ESC Committee for Practice Guidelines 2016-2018



35/49

Bueno Hector - Pfizer : Apixaban (2016-2017)

- Bristol Myers Squibb : Apixaban (2016-2017)

- Bayer : Aspirin, rivaroxaban (2016-2017)

- MEDSCAPE-the heart.og : Inespecific (2016-2017)

- Astra Zeneca : Ticagrelor (2016-2017)

- Ferrer Internacional : Trinomia (polypill) (2016-2017)

- Sanofi Aventis : PCSK9 inhibitors (2017)

- Novartis : Serelaxin, ACZ885, AHF Academy, (2017)



E - Research funding (personal).- Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016)

- BMS : CV013-011 - STANDUP-AHF trial (2016-2017)

- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016-2017)

- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016-2017)

- Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- FAHA (2016)

- VP elect. Spanish Society of Cardiology FAHA (2017)

24/08/2018




36/49

Coca Antonio 1- Financial Declaration


- Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016)

- Merck Serono : Bisoprolol-Amlodipine (2016-2017)

- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016-2017)

- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2016-2017)

Collet Jean-Philippe 1- Financial Declaration


- BMS : apixaban (2016)

- Sanofi Aventis : CLOPIDOGREL (2016)

- Medtronic : corevalve (2016)

- Eli Lilly : PRASUGREL (2016)

- Astra-Zeneca : ticagrelor (2016)

- MSD : VORAPAXAR (2016)

- Bayer Healthcare : xarelto (2016)

- Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017)

- Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017)

- Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017)

- Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Bristol Myers Squibb : APIXABAN (2016)

- Medtronic : COREVALVE (2016)

24/08/2018




37/49

Collet Jean-Philippe - Stago : LABORATORY TEST (2016)

- Eli Lilly : PRASUGREL (2016)

- FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)

- ICAN : THROMBOSIS (2016)

- Astra Zeneca : TICAGRELOR (2016)

- Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017)

- Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017)

- Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017)

- Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

- Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

Coman Ioan Mircea 1- Financial Declaration


- Daiichi Sankyo : anticoagulants (2016-2017)

- Johnson & Johnson : antithrombotic (2016-2017)

- Bayer AG : antithrombotic (2016-2017)

- Sanofi Aventis : dyslipidemia (2016-2017)

- Fournier Laboratories : dyslipidemia (2016-2017)

- Amgen Inc : dyslipidemia , (2016-2017)

- Novartis : HF (2016-2017)

24/08/2018




38/49

Coman Ioan Mircea - Vifor International : iron deficiency (2016-2017)

- Actelion : PHT (2016-2017)


- Daiichi Sankyo : anticoagulants (2016-2017)

- Johnson & Johnson : antithrombotic (2016-2017)

- Bayer AG : antithrombotic (2016-2017)

- Sanofi Aventis : dyslipidemia (2016-2017)

- Amgen Inc : dyslipidemia (2016-2017)

- Fournier Laboratories : dyslipidemia (2016-2017)

- Novartis : HF (2016-2017)

- Vifor International : iron deficiency (2016-2017)

- Actelion : PHT (2016-2017)

Delgado Victoria 1- Financial Declaration


- Abbott Vascular : Mitraclip (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : Pacemaker-Heart failure (2016)

- Medtronic : Pacemaker-Heart failure (2016)

- Biotronik : Pacemaker-Heart Failure (2016)

- Edwards Lifesciences : Valvular heart disease (2016)

- Boston Scientific : pacemakers (2017)

- Medtronic : pacemakers (2017)

24/08/2018




39/49

Delgado Victoria - Biotronik : pacemakers (2017)

- Edwards Lifesciences : valves (2017)

Fitzsimons Donna


Gaemperli Oliver 1- Financial Declaration


- GE-Healthcare : Imaging (2016)

- Amgen Inc : PCSK9 (2016)

- Servier : Procorolan (2016)

- GE Healthcare : Imaging (2017)

Hindricks Gerhard 1- Financial Declaration


- Boston Scientific : CIEDs and interventional electrophysiology (2016)

- St Jude Medical : CIEDs and interventional electrophysiology (2016)

- Biotronik : CIEDs and interventional electrophysiology (2016)

- Abbott : Pacemaker, Ablation (2017)

- Biosense Webster : Pacemaker, Ablation (2017)

- Biotronik : Pacemaker, catheter (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : CIEDs and interventional electrophysiology (2016)

- St Jude Medical : CIEDs and interventional electrophysiology (2016)

- Abbott, Biotronik, Medtronic, Boston Scientific : Electropyhsiology, arrhythmias (2017)

24/08/2018




40/49

Hindricks Gerhard 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the

Helios Hospital Group. (2017)

Iung Bernard 1- Financial Declaration


- Edwards Lifesciences : Heart Valve Prostheses (2016-2017)


- Novartis : Heart failure drugs (2017)

Juni Peter



D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : Anti-platelet Therapy (2017)

- Biotronik : Drug-eluting stents (2017)

- Biosensors International Group : Drug-eluting stents (2017)

- The Medicines Company : Thrombin inhibitors (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly

and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)

24/08/2018




41/49

Katus Hugo 1- Financial Declaration


- Daiichi Sankyo : Lixiana_NOAK (2016-2017)


- Bayer Vital : Xarelto-NOAK (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : Biobank (2016-2017)

- Philips : MRT (2016-2017)

Knuuti Juhani 1- Financial Declaration


- Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017)

- GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Orion : Brain diseases (2016)

- AC Immune : Brain diseses (2016)

- Antaros : Endocrinology (2016)

- Boehringer-Ingelheim : Neurology (2016)

- MSD : Neurology (2016)

- GE Gealthcare : Neurology (2016)

Lancellotti Patrizio 1- Financial Declaration


- St Jude Medical : Echo course (2016)

24/08/2018




42/49

Lancellotti Patrizio - Servier : Ischemic Heart Disease (2016-2017)


- Medtronic : Structural disease (2016)

- Bayer : NOAC (2016-2017)

Leclercq Christophe 1- Financial Declaration


- Sorin Group : devices (2016)

- St Jude Medical : devices (2016)

- Bayer Healthcare : DOAC (2016)

- Boston Scientific : devices (2016-2017)

- Medtronic : devices (2016-2017)

- Biotronik : devices (2016-2017)

- Abbott : devices (2017)

- LIvanova : devices (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Biotronik : devices (2017)

McDonagh Theresa 1- Financial Declaration


- Vifor International : Ferrinject (2016-2017)

- Novartis : Honoraria (2016-2017)

- Bayer AG : Honoraria (2017)

24/08/2018




43/49

Piepoli Massimo Francesco




- Servier : Committee member, Speaker fee (2016)

- Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016)

- Amgen : Metabolic, Lipid (2016)


- Novartis : Heart Failure Prevention Initiatives (2016)

Ponikowski Piotr 1- Financial Declaration


- Abbott Vascular : devices (2016)

- BioControl : devices (2016)

- Pfizer : lipids (2016)

- Boehringer-Ingelheim : anticoagulant, diabetes (2016-2017)

- Respicardia : devices (2016-2017)

- Novartis : heart failure (2016-2017)

- Cardiorentis : heart failure (2016-2017)

- Berlin Chemie AG : heart failure (2016-2017)

- Bayer Healthcare : heart failure (2016-2017)

- Vifor Pharma ltd : heart failure (2016-2017)

24/08/2018




44/49

Ponikowski Piotr - CIBIEM : heart failure (2016-2017)

- Servier : heart failure, coronary artery disease (2016-2017)

- Amgen : heart failure, lipids (2016-2017)

- Pfizer : lipids, heart failure (2017)


- DC Device : devices (2016)

- Cardiorentis : heart failure (2016)

- Respicardia : anticoagulant (2016-2017)

- BioControl : devices (2016-2017)

- Novartis : heart failure (2016-2017)

- Bayer Healthcare : heart failure (2016-2017)

- CIBIEM : heart failure (2016-2017)

- Servier : heart failure, coronary artery disease (2016-2017)

- Amgen : heart failure, lipids (2016-2017)

- Cardionomic : devices (2017)

- Impuls Dynamics : devices (2017)

- National Institute of Health : heart failure (2017)

- European Union grant : heart failure, prevention (2017)

Richter Dimitrios 1- Financial Declaration


- Angelini : Lipids (2016)

24/08/2018




45/49

Richter Dimitrios - Swisspharma : lipids-hypertension (2016)

- Astra Zeneca : lipids-thrombosis (2016)

- Pfizer : lipids-thrombosis (2016)

- Winmedica : lipids-thrombosis (2016)

- Boehringer-Ingelheim : thrombosis (2016)

- Menarini : CAD- hypertension (2016-2017)

- Novartis : hypertension (2016-2017)

- Abbott : lipids (2016-2017)

- Amgen : lipids (2016-2017)

- Sanofi Aventis : Lipids (2016-2017)

- Lilly : Lipids (2016-2017)

- Unilever : lipids (2016-2017)

- Merck Sharp & Dohme : lipids (2016-2017)

- Vianex : lipids (2016-2017)

- Galenica : Lipids (2016-2017)

- Teva Pharmaceutical Industries : lipids, hypertension (2016-2017)

- Bayer Healthcare : Thrombosis (2016-2017)

- Edwards Lifesciences : aortic stenosis (2017)

- Novo-Nordisk : diabetes (2017)

- Unipharma : hypertension-thrombosis (2017)

24/08/2018




46/49

Roffi Marco 1- Financial Declaration


- Terumo Inc : coronary catheters (2016)

- Johnson & Johnson : coronary catheters (2016)

- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : devices (2016)

- Medtronic : devices (2016)

- Biotronik : devices (2016)

- Terumo Inc : devices (2016)

- Abbott Vascular : devices (2016)

- Boston Scientific : Stents (2017)

- Medtronic : Stents (2017)

- Biotronik : stents (2017)

- Terumo Inc : stents (2017)

- Abbott Vascular : stents (2017)

Shlyakhto Evgeny 1- Financial Declaration


- Krka Pharma : Arterial Hypertension (2016-2017)

- Novartis : Arterial Hypertension, Heart Failure (2016-2017)

- Merck Sharp & Dohme : Atherosclerosis (2016-2017)

- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016-2017)

24/08/2018




47/49

Shlyakhto Evgeny - Pfizer : General Cardiology (2016-2017)

Simpson Iain A 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Member and Past President of the British Cardiovascular Society Member of the Management Board of the American

College of Cardiology National Cardiovascular Data Registries (2016-2017)

Sousa Uva Miguel




- Boehringer-Ingelheim : Dabigatran (2016)



Windecker Stephan 1- Financial Declaration


- Bayer AG : General Cardiology (2017)

- Abbott : Invasive Cardiology (2017)

- Boston Scientific : Invasive Cardiology (2017)

- Edwards Lifesciences : invasive Cardiology (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : General Cardiology (2016)

- Terumo Inc : General Cardiology (2016)

- Bracco Pharmaceutical : General Cardiology (2016)

- Boston Scientific : General Cardiology (2016-2017)

24/08/2018




48/49

Windecker Stephan - Abbott : General Cardiology (2017)

- St. Jude Medical : General Cardiology (2017)

- Amgen Inc. : General Cardiology (2017)

- Symetis SA : Invasive Cardiology (2017)

- Biotronik : Invasive Cardiology (2017)

- Terumo Inc : Invasive Cardiology (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational

and Entreprenieur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)

Zamorano Gomez Jose Luis



- Philips : 3D Echocardiography. (2016)

- Servier : Clinical case presentation during ESC Cong 2016 (2016)

- Pfizer : speaker CV risk factors. (2016)

- MSD : speaker. CV risk factors (2016)

- Bayer : afib (2017)

- Pfizer : Afib (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016)

- Abbott : Epidemiology study of Mitral regurgitation (2016)

24/08/2018




49/49

Documents

2018 ESC Guidelines for the management of cardiovascular ... · 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Task Force Expert Type of Relationship